Milan, Italy (December 6, 2023)
Today, MgShell, a MedTech company that aspires to inspire a change in ophthalmology by developing a magnesium-based drug delivery platform capable of reshaping patient care and enhancing treatment adherence for patients suffering from retinal diseases, announced its collaboration with Prof. Diego Mantovani, who joins the team as Scientific Advisor.
Renowned in the field of biomaterials and biometals for clinical applications, Prof. Mantovani is set to bring a wealth of expertise, innovation, and a deep passion for cutting-edge advancements to the journey of the company. With his guidance, the company is poised to navigate the intricate realms of drug-delivery, ensuring our magnesium-based solutions stand at the forefront of scientific excellence.
About Prof. Diego Mantovani:
Holder of the Canada Research Chair in Biomaterials and Bioengineering for the Innovation in Surgery and Full Professor at the Department of Materials Engineering at Laval University, Prof. Mantovani is a recognised specialist in biomaterials. He has authored more than 350 original articles, holds 5 patents, and presented more than 210 keynotes, invited and seminar lectures worldwide in the field of advanced materials for biomedical applications. As a result, his works received more than 15,000 citations.
About MgShell:
MgShell, headquartered in Milan, Italy, is a preclinical-stage drug delivery company focused on developing a magnesium-based drug delivery platform capable of reshaping patient care, enhancing treatment adherence for patients suffering from retinal diseases, and lowering healthcare expenses.
